Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Locus Biosciences

Main focus: New treatments against bacterial infections

Company stage: Clinical

Diseases: Urinary tract infection, other infections

Genome editing tool: CRISPR-Cas3

Funding stage: Private

Location: North Carolina, USA


Partners: Janssen Pharma

Locus Biosciences is a clinical-stage gene-editing company focused on treating bacterial infectious diseases. The company uses its next generation sequencing-based platform to rapidly identify new bacterial targets and phages. Locus uses CRISPR-Cas3 crPhages as the base of their therapies. The phages are designed using machine learning in order to optimise effectiveness against new bacterial targets.


HashtagLOCUS Biosciences, Inc.

Company: Locus Biosciences
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine